Understand FDA QSIT inspection changes and CP 7382.850. Explore key FAQs on audits, checklists, sampling, and risk‑based inspection expectations.
Discover how governance, process standardization, and digital technology transform QMS harmonization into a scalable enterprise capability.
USP <665> goes live in 2026. Are your polymer components compliant? Learn why early risk assessment is the key—and how to prepare.
Read how FDA’s new CSA guidance simplifies software assurance with a risk-based, least-burdensome approach.
Scaling globally? Discover why harmonization is a strategic necessity, not a choice.
AI is transforming pharmacovigilance. Learn why strong human oversight remains essential to ensure patient safety and regulatory compliance.
Introducing AI requires more than technology. Learn how to secure organizational support, and build a foundation for compliant AI adoption.
Digitalization and new regulations are transforming C&Q, driving a shift toward risk‑based, data‑driven, and fully digital validation practices.
ICH M14 provides a global framework for non‑interventional studies using real‑world data, enhancing transparency, consistency, and methodological.
ICH E6(R3) Annex 2 draft reshapes GCP for decentralized and real-world data–driven trials.
